-

Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board

Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company’s Board of Directors.

Kåre Schultz brings a unique global perspective on the healthcare and pharmaceutical industries from his decades of leadership experience at several international organizations, including Teva Pharmaceutical Industries, Lundbeck, and Novo Nordisk. Mr. Schultz spent over 25 years at Novo Nordisk, where he served in many capacities, most notably as President and COO as the company established itself as a leading company in diabetes care. As CEO of Teva Pharmaceutical Industries, Mr. Schultz streamlined operations to focus the company on its core strengths in generics and specialty medicines. Mr. Schultz also served as CEO of Lundbeck, where he helped position the company as a leader in the pharmaceutical industry.

“We are in a transformative moment for healthcare with the opportunity to make life-changing treatments accessible to all who need it. Kåre’s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare, and technology to redefine health and wellness for our customers,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “We’re honored to have Kåre join us to share his perspective and leadership as we continue to serve more customers across our platform.”

“Hims & Hers is on a trajectory to upend the healthcare industry,” said Kåre Schultz. “In my long career in the pharmaceutical industry, this is the first company I have seen that is leveraging today’s modern tools to truly break down barriers and change the status quo of how people access the health solutions they need to live their fullest lives. I’m thrilled to be a part of this journey.”

Mr. Schultz joins leaders from across industries on the Hims & Hers Board of Directors including: former CEO of the Cleveland Clinic, Dr. Toby Cosgrove; tech industry leader, Christopher Payne; US regulatory and foreign policy expert, Anja Manuel; former Chief Medical Officer of Walgreens and current Chief Medical Officer of Hims & Hers, Patrick Carroll; former CFO of Netflix, David Wells; consumer retail expert, Christiane Pendarvis; and former Nike and Sony marketing executive, Andrea Perez.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Press Contact
Abby Reisinger
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Abby Reisinger
press@forhims.com

More News From Hims & Hers

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company’s ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia a...

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. By leveraging nearly a decade of infrastructur...

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

SAN FRANCISCO--(BUSINESS WIRE)--Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care....
Back to Newsroom